66 related articles for article (PubMed ID: 1927118)
1. [Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma].
Mallmann P; Krebs D
Zentralbl Gynakol; 1991; 113(12):689-96. PubMed ID: 1927118
[TBL] [Abstract][Full Text] [Related]
2. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
Mallmann P; Dietrich K; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
[TBL] [Abstract][Full Text] [Related]
3. [The effect of adjuvant combined chemo/immunotherapy on immunological parameters and clinical course in patients with breast carcinoma].
Mallmann P; Krebs D
Zentralbl Gynakol; 1991; 113(12):697-706. PubMed ID: 1927119
[TBL] [Abstract][Full Text] [Related]
4. Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin.
Mallmann P; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Jun; 12(5):333-40. PubMed ID: 2232966
[TBL] [Abstract][Full Text] [Related]
5. Determination of TNF alpha, interferon alpha, interleukin 2 and reactivity in the leucocyte migration inhibition test in breast cancer patients.
Mallmann P; Diedrich K; Mallmann R; Koenig UD; Krebs D
Anticancer Res; 1991; 11(4):1509-15. PubMed ID: 1746907
[TBL] [Abstract][Full Text] [Related]
6. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
7. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
Premkumar VG; Yuvaraj S; Vijayasarathy K; Gangadaran SG; Sachdanandam P
Basic Clin Pharmacol Toxicol; 2007 Jun; 100(6):387-91. PubMed ID: 17516992
[TBL] [Abstract][Full Text] [Related]
9. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
10. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
11. [Improvement of host-immunity by adjuvant therapy with juzen-taiho-to for patients with brain tumors].
Miyagami M; Katayama Y
No Shinkei Geka; 2003 Apr; 31(4):401-9. PubMed ID: 12704821
[TBL] [Abstract][Full Text] [Related]
12. In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer.
Robinson E; Rubin D; Mekori T; Segal R; Pollack S
Cancer Immunol Immunother; 1993 Aug; 37(3):209-12. PubMed ID: 8334683
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of serum T-lymphocyte subsets and NK cell activity in patients with hypopharyngeal squamous cell carcinoma].
Chen WK; Song M; Chen FJ; Guo ZM; He LR; Yan SL
Ai Zheng; 2006 Oct; 25(10):1300-2. PubMed ID: 17059781
[TBL] [Abstract][Full Text] [Related]
15. NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer.
Cosiski Marana HR; Santana da Silva J; Moreira de Andrade J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):318-23. PubMed ID: 10985887
[TBL] [Abstract][Full Text] [Related]
16. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study.
Mozaffari F; Lindemalm C; Choudhury A; Granstam-Björneklett H; Lekander M; Nilsson B; Ojutkangas ML; Osterborg A; Bergkvist L; Mellstedt H
Cancer Immunol Immunother; 2009 Jan; 58(1):111-20. PubMed ID: 18488220
[TBL] [Abstract][Full Text] [Related]
17. Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus.
Westerterp M; Boermeester MA; Omloo JM; Hulshof MC; Vervenne WL; Lutter R; Out TA; van Lanschot JJ
Cancer Immunol Immunother; 2008 Dec; 57(12):1837-47. PubMed ID: 18398607
[TBL] [Abstract][Full Text] [Related]
18. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
